TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Détails

Ressource 1Télécharger: fimmu-08-01203.pdf (1235.68 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_5787FD5D2175
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.
Périodique
Frontiers in immunology
Auteur(s)
Kaufmann SHE, Dockrell H.M., Drager N., Ho M.M., McShane H., Neyrolles O., Ottenhoff THM, Patel B., Roordink D., Spertini F., Stenger S., Thole J., Verreck FAW, Williams A.
Collaborateur(s)
TBVAC2020 Consortium
Contributeur(s)
Britton W., Triccas J., Counoupas C., Grooten J., Demoitie M.A., Romano M., Mascart F., Andersen P., Aagaard C., Christensen D., Ruhwald M., Lindenstrom T., Neyrolles O., Charneau P., Guilhot C., Peixoto A., Gilleron M., Locht C., Brosch R., Inchauspe G., Long SLT, Kaufmann S., Weiner J., Maertzdorf J., Neuwenhuizen N., Bastian M., Stenger S., Caccamo N., Goletti D., Nisini R., Shin S.J., Lee H., Sigal A., Scriba T., Walzl G., Loxton A., Wilkinson R., Cardona P.J., Vilaplana C., Martin C., Marinova D., Aguilo N., Spertini F., Aebersold R., Caron E., Pinschewer D., De Libero G., Siegrist C.A., Collin N., Barnier-Quer C., Sander P., Verreck F., Ottenhoff T., Joosten S., van Meijgaarden K., Coppola M., Geluk A., Drager N., Roordink D., Thole J., Perrie Y., Baird M., Levin M., Dockrell H., Smith S., Fletcher H., Bancroft G., Rawkins A., Clark S., Ho M.M., McShane H., Satti I., Stylianou E., Vordermeier M., Hogarth P.
ISSN
1664-3224 (Print)
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
8
Pages
1203
Langue
anglais
Résumé
TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Mots-clé
bacille Calmette–Guérin, biomarker, clinical trial, discovery, portfolio management, tuberculosis, vaccination
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/12/2017 16:19
Dernière modification de la notice
20/08/2019 15:11
Données d'usage